About This Blog

When you're purchasing research peptides, one number matters most: purity. But what does "99.1% pure" actually mean? And how do you know a certificate of analysis (COA) is legitimate? In this guide, we'll walk you through peptide quality standards, how purity is measured, and what red flags to watch for when sourcing research-grade compounds.

A 2026 market-news look at West Virginia University pharmacy experts' call for stronger evidence behind the multibillion-dollar peptide industry, and why third-party-verified sourcing matters most for anyone doing research today.

BPC-157 remains one of the most discussed compounds in the peptide research community, but interest in it has outpaced the published science. Here's what the current evidence actually shows, and why purity and testing matter more for this peptide than most.

Tirzepatide is best known for its glucose- and weight-lowering effects, but a newly published study adds evidence for another benefit: a real reduction in serious cardiovascular events. Published in The British Medical Journal, it's one of the largest real-world looks yet at how tirzepatide performs on cardiovascular outcomes outside a clinical trial setting.

Peptides are prized for their ability to drive specific biological processes like bone formation and tissue repair, but their small size has always worked against them in drug delivery: once placed in water-rich materials like hydrogels, they tend to diffuse away long before healing is complete. A new Rice University study, published in Cell Biomaterials, offers a surprisingly simple fix.

Harvard Health Publishing recently examined the fast-growing world of injectable peptides, from FDA-approved medications like insulin and GLP-1 drugs to the unregulated compounds sold online for research and personal use. Their findings offer a useful checkpoint for anyone following the peptide space, including everyone in our own research community.

A new nonprofit is building the first peptide-specific accreditation standards for compounding and sourcing, just as regulators weigh whether to expand access to several popular research peptides.

The FDA advisory panel's vote to ease restrictions on six peptides made headlines this week. But the vote wasn't as clear-cut as the headlines suggest. Behind the scenes, FDA's own scientific staff recommended against it, several panel members have documented industry ties, and the peptides in question are already circulating on the unregulated gray market. Here's what the coverage is missing.

Last month's FDA advisory panel vote on peptide compounding made headlines everywhere — but it's created almost as much confusion as clarity. Here's what actually changed, what hasn't, and what to expect next.